MYND Life Sciences Announces Update on Payment Obligations Under Unsecured Convertible Debentures
MYND Life Sciences Announces Update on Payment Obligations Under Unsecured Convertible Debentures
MYND Life Sciences was formed to commercialize proprietary biomarker diagnostic tests and novel therapeutics for patients suffering from MDD, TRD and other neuro-inflammatory disorders
MyND生命科學公司成立的目的是將專有的生物標記物診斷測試和新療法商業化，用於MDD、TRD和其他神經炎性疾病患者
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2023) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company") today announces it has not made its payment obligations under its unsecured convertible debentures issued on September 8, 2021 with a total principal amount of $3,000,000 (collectively, the "Convertible Debentures").
溫哥華，不列顛哥倫比亞省-(Newsfile Corp.-2023年9月11日)-MyND生命科學公司(CSE：MYND)(場外市場：MYNDF)(“我的名字“或”公司“)今天宣佈，尚未履行其於2021年9月8日發行的本金總額為3,000,000美元的無擔保可轉換債券的償付義務(統稱為可轉換債券“)。
Pursuant to the terms of the Convertible Debentures, the Company was required to pay the principal amounts and accrued interest thereon by no later than September 8, 2023 (the "Maturity Date"). As of the date of this press release, the Company has neither: (i) paid the principal amounts or the accrued interest thereon; nor (ii) agreed upon a repayment plan for such amounts with the holders of the Unsecured Convertible Debentures. Leading up to the Maturity Date, the Company has had ongoing discussions with certain holders of the Unsecured Convertible Debentures regarding potential terms for amending the Unsecured Convertible Debentures, including an extension of the Maturity Date. Those discussions are on-going and the Company is continuing to evaluate alternatives available to it. The Company announced today that it has formed a special committee. The mandate of the special committee will be to evaluate the Company's alternatives specifically as it relates to its outstanding unsecured convertible debentures and to make recommendations to the Board of Directors. This committee undertakes to communicate with bondholders within 30 days from now.
根據可換股債券的條款，本公司須於2023年9月8日前支付本金及應計利息(“到期日“)。截至本新聞稿發佈之日，公司尚未：(I)支付本金或本金應計利息；(Ii)也未與無擔保可轉換債券持有人就該等款項的償還計劃達成一致。在到期日之前，本公司一直與無抵押可轉換債券的某些持有人就修訂無抵押可轉換債券的可能條款進行討論，包括延長到期日。這些討論正在進行中，該公司正在繼續評估其可用的替代方案。公司今天宣佈，它已經成立了一個特別委員會。特別委員會的任務將是具體評估公司與其未償還的無擔保可轉換債券有關的替代方案，並向董事會提出建議。該委員會承諾從即日起30天內與債券持有人進行溝通。
ABOUT MYND LIFE SCIENCES INC.
關於我的生命科學公司。
MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuropharmaceutical and novel drug development, diagnostics and vaccines. MYND is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by unique molecular concepts for the applications of psilocybin analogs for overcoming disease. The Company advances pharmaceutical developments through rigorous science and clinical trials while diligently patenting and safeguarding its intellectual property.
我的名字生命科學公司是一家專注於神經藥物和新藥開發、診斷和疫苗的醫用生物技術藥物研究和開發公司。我的名字正在開發新的生物實體(NBE)和新的化學實體(NCE)，並通過獨特的分子概念將自己與其他(生物)製藥公司區分開來，應用裸蓋菇素類似物克服疾病。該公司通過嚴格的科學和臨床試驗推動藥物開發，同時努力申請專利並保護其知識產權。
For more information and to subscribe to MYND's mailing list, please visit .
欲瞭解更多資訊並訂閱MyND的郵件列表，請訪問。
CONTACT INFORMATION
聯繫資訊
Dr. Lyle Oberg, MD, CEO
Email: ir@myndsciences.com
Web:
Lyle Oberg博士，醫學博士，首席執行官
電子郵件：ir@myndcerences.com
網頁：
Forward-Looking Statements
前瞻性陳述
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.
本新聞稿包含符合適用證券法規的前瞻性陳述和資訊。前瞻性陳述和資訊常常但不總是可以通過使用諸如“計劃”、“預期”或“不預期”、“預期”、“估計”、“打算”、“預期”或“不預期”或“相信”等詞語或這些詞語的變體來識別，或陳述某些行動、事件或結果“可能”、“可能”、“將”、“可能”或“將”被採取、發生或實現。前瞻性陳述或資訊涉及已知和未知的風險、不確定性和其他因素，可能導致MyND的實際結果、業績或成就與本新聞稿中包含的前瞻性陳述或資訊明示或暗示的任何未來結果、業績或成就大不相同。
Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
前瞻性資訊涉及的風險、不確定性和其他因素可能導致實際事件、結果、業績、前景和機會與此類前瞻性資訊明示或暗示的情況大不相同。加拿大證券交易所沒有對本新聞稿內容的充分性或準確性進行審查，也不承擔任何責任。
None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.
與此次發行相關的任何證券都不會根據修訂後的《1933年美國證券法》(下稱《1933年法案》)進行註冊，而且如果沒有註冊或獲得1933年法案註冊要求的適用豁免，這些證券都不能在美國發行或出售。本新聞稿不應構成出售要約或徵求購買要約，也不應在任何這樣的要約、招攬或出售將是非法的任何州出售證券。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。